| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 09/26 15:17 | globenewswire.com |
| Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial | 09/15 08:45 | globenewswire.com |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 09/10 16:06 | globenewswire.com |
| Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference | 08/26 12:26 | globenewswire.com |
| Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab | 08/23 11:55 | seekingalpha.com |
| TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma | 08/19 14:00 | globenewswire.com |
| Genmab Announces Changes to its Executive Committee | 08/16 09:00 | globenewswire.com |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 08/13 14:53 | globenewswire.com |